FDA advisers vote against sleep peptide as they debate safety and health claims
The FDA's advisory committee is meeting for two days to discuss whether seven peptides — which have become popular in wellness circles — should be allowed to be compounded.
The FDA's advisory committee is meeting for two days to discuss whether seven peptides — which have become popular in wellness circles — should be allowed to be compounded.
A group of experts advising the Food and Drug Administration voted "no" for the first time on reclassifying a peptide, citing safety and efficacy unknowns.
Intraday Data provided by FACTSET and subject to terms of use . Historical and current end-of-day data provided by FACTSET . All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
Sinergia Empresarial continuará el seguimiento de esta información sobre fDA advisers vote against sleep peptide as they debate safety and health claims y ampliará la cobertura conforme se confirmen nuevos elementos relevantes para el ecosistema empresarial.
